Device Manufacturers Drive Education In China Amid Looming Tender Expansion
This article was originally published in PharmAsia News
China’s device market is poised for extraordinary growth with multinational firms such as Johnson & Johnson, Smith & Nephew and Stryker ramping up physician education against a backdrop of regulatory complexity and a possible new central tendering process.
You may also be interested in...
U.S.-listed orthopedic device maker Zimmer Inc. says its latest overseas purchase of Beijing Montagne Medical Device Co. Ltd., gives it greater marketing access to the Chinese orthopedic implant market, growing at an estimated 15 percent annually, and a manufacturing base to compete with rivals already in the market
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
Increasingly looking to China to commercialize their latest therapies, multinationals may be leaping into unknown waters to navigate an intellectual property judiciary and administrative maze, in a country where some copy drugs have been approved before patent expiry. With a government trying to balance innovation and access, two recent rulings involving AstraZeneca shed rare light onto China’s protections for innovation, with advisors pointing to challenges and success factors.